Eli Lilly and Company has announced its agreement to acquire Verve Therapeutics, aiming to advance Verve’s one-time, in vivo gene-editing therapies for cardiovascular disease. The acquisition terms include a fixed cash payment per Verve share, along with potential additional milestone-based payments. This move strengthens Lilly’s position in the cardiovascular space and builds on its existing collaboration with Verve to develop gene-editing treatments targeting key cardiovascular risk factors, including PCSK9, ANGPTL3, and lipoprotein(a) [Lp(a)].

Through this acquisition, Lilly plans to integrate Verve’s gene-editing platform to further develop its pipeline of single-administration therapies designed to address inherited cardiovascular conditions. The combined expertise is expected to support the development of long-term treatment options for patients with high unmet needs in cardiovascular care. Lilly’s strategy focuses on delivering potentially durable solutions that may help reduce cardiovascular risk with a one-time treatment approach.